Having trouble finding your antibody linker to the clinic?
We can help.
From immunization to nanobodies and beyond, the field of antibody development is a vast ocean.
At Vivogenia, we bridge the gap between initial target identification and a validated clinical lead. Developing a therapeutic antibody is no longer just about finding a binder; it is about engineering a molecule that is potent, specific, stable, and ready for large-scale manufacturing.
The failure rate in biologics development is often tied to late-stage "developability" issues, lack of functional efficacy or adverse effects that weren’t picked up beforehand. Our approach integrates discovery and engineering to solve these problems early on.
Modern-day antibody development scales exponentially in complexity. From linker selection to payload configuration, the configurations for your asset can be mind-boggling. It is this same complexity that makes developing a best-in-class antibody a struggle as well.
Antibody Simulator
Configure dual-affinity architectures and simulate development parameters.
IgG Bispecific
The data and visual representations provided by this platform are based on predictive simulations and simplified pharmacokinetic models for research and educational purposes only. Results do not constitute clinical, medical, or legal advice. Antibody stability, developability, and therapeutic efficacy are subject to complex biological variables and must be validated through laboratory testing.
- Wrong Target: Antigen may not drive disease pathology.
- Conformation: Synthetic antigen may not mimic natural structure.
- Tolerance: Host recognizes antigen as "self".
- Immunodominance: Response targets non-functional epitopes.
- Sensitivity: Assays miss low-abundance binders.
- False Positives: Candidates bind non-specifically in vitro.
- Toxicity: Off-target binding damages healthy tissue.
- Immunogenicity: Body attacks the drug (ADA).
- Poor PK: Rapid clearance reduces efficacy.
- Aggregation: Antibodies clump, causing safety risks.
- Low Yield: Cell lines fail to produce commercially viable amounts.
- Instability: Degradation during storage.
- Rejection: Incomplete safety data or study flaws.
- Compliance: Failure to meet GMP standards.
With near-endless antibody (and nanobody) configurations, targets and epitopes, comes near-endless obstacles that can impede your antibody development program.
There is nothing quite like the frustration of watching a promising project stall because your Antibody-Drug Conjugate (ADC) just isn’t behaving.
Maybe your antibody lost its binding affinity the moment you attached the linker. Or perhaps your "magic bullet" is falling apart in systemic circulation, releasing the payload way too early and hitting everything except the tumor. Maybe there’s an anti-drug antibody response to your lead candidate, which didn’t pop up in your in vivo studies, but suddenly it’s in the clinic.
We’ve seen these challenges, so you don’t have to figure out what’s going to be the next problem to solve.